Product Images Fluticasone Propionate And Salmeterol Diskus
View Photos of Packaging, Labels & Appearance
- Remedy_Label - Remedy Label
- Fluticasone propionate chemical structure - fp sal spl graphic 01
- Salmeterol xinafoate chemical structure - fp sal spl graphic 02
- Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
- Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
- Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
- Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
- Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
- Figure A - fp sal spl graphic 08
- Figure B - fp sal spl graphic 09
- Figure C - fp sal spl graphic 10
- Figure D - fp sal spl graphic 11
- Figure E - fp sal spl graphic 12
- Figure F - fp sal spl graphic 13
- Figure G - fp sal spl graphic 14
- Figure H - fp sal spl graphic 15
Product Label Images
The following 16 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 70518-4348 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
This text provides information about Fluticasone Propionate/Salmeterol Inhalation Diskus medication, which comes in a powder form with a strength of 500mcg/50mcg. The package contains 60 blisters and should be stored in a dry place away from direct heat or sunlight. It is for oral inhalation only and should be discarded one month after opening. The usual dosage instructions can be found in the insert. The medication is repackaged by RemedyRepack Inc. and manufactured by Prasco Laboratories. The lot number and NDC information are included for tracking purposes. It is important to keep this medication out of reach of children and store it within the specified temperature range.*
Fluticasone propionate chemical structure - fp sal spl graphic 01
Salmeterol xinafoate chemical structure - fp sal spl graphic 02
Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
This description is not clear as it seems to be a list of medication names and dosages along with some numerical values related to pulmonary function tests. It is not possible to generate a useful description based on this text.*
Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
This text provides information on a clinical study comparing different treatments for respiratory conditions based on the change in FEV4 (Forced Expiratory Volume in 4 seconds). The study includes groups receiving a combination of Fluticasone propionate/salmeterol, salmeterol alone, fluticasone propionate alone, and a placebo. The number of participants in each group is also provided, with the baseline measurement taken on Day 1.*
Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
This is a comparison of the percentage change in Forced Expiratory Volume (FEV) relative to the baseline measurement taken on Day 1. The study involves different treatment groups including Fluticasone propionate/salmeterol, Salmeterol alone, Fluticasone propionate alone, and a Placebo group. The measurements were taken at different time points, from Day 1 to Week 12. The number of participants (N) in each treatment group is specified.*
Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
This is a description of a clinical study comparing the efficacy of Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily with Salmeterol 50 mcg twice daily and Placebo in patients with baseline FEV1 values. The study tracked measurements over a period of weeks and recorded the corresponding FEV1 values for each group. The data suggests that Fluticasone propionate/salmeterol DISKUS 250/50 mcg had a positive impact on the FEV1 values compared to the Salmeterol 50 mcg and Placebo groups.*
Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
The text is not readable.*
Figure A - fp sal spl graphic 08
This is a description for a medication called Putiasone with Salmeterol DISKUS inhalation powder. The device consists of a mouthpiece and a lever for administering the medication.*
Figure B - fp sal spl graphic 09
Figure C - fp sal spl graphic 10
Figure D - fp sal spl graphic 11
Figure E - fp sal spl graphic 12
Figure F - fp sal spl graphic 13
Figure G - fp sal spl graphic 14
Figure H - fp sal spl graphic 15
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
